Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 30

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 30
---
s) following the consummation of this offering and enable the investors to make an investment in our securities without exceeding such beneficial ownership limitation, by receiving pre-funded warrants in lieu of ADSs which would result in such ownership of more than 4.99% (or, at the election of the holder, 9.99%) and receive the ability to exercise their option to purchase the ADS underlying the pre-funded warrants at such nominal price at a later date. Duration and Exercise Price Each pre-funded warrants is exercisable for one ADS, with an exercise price equal to $0.0001 per ADS, at any time that the pre-funded warrants is outstanding. There is no expiration date for the pre-funded warrants. The holder of pre-funded warrants will not be deemed a holder of our underlying ADSs until the pre-funded warrants is exercised. Exercisability A holder of pre-funded warrants will not have the right to exercise any portion of its pre-funded warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates or any other persons whose beneficial ownership of ADSs or ordinary shares would be aggregated with the holder’s or any of the holder’s affiliates) would beneficially own a number of ADSs in excess of 4.99% (or, at the election of the holder, 9.99%) of the ordinary shares (including ordinary shares represented by ADSs) then outstanding after giving effect to such exercise. However, any pre-funded warrant holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder to us. The exercise price and the number of ADSs issuable upon exercise of the pre-funded warrants is subject to appropriate adjustment in the event of recapitalization events, share dividends, share splits, share combinations, reclassifications, reorganizations or similar events affecting our ADSs or ordinary shares. S - 16 Cashless Exercise In lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ADSs determined according to a formula set forth in the pre-funded warrants. Fundamental Transaction In the event of a Fundamental Transaction, then upon any subsequent exercise of the pre-funded warrants, a holder thereof will have the right to receive the